RxDoctor Payments Data

Gordi Khera, MD

Cardiovascular Disease · Glendale, AZNPI 1104880996

Payments from drug & device makers

$29,013in general payments, 2019–2025

Across 181 payments — averaging $160.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$20K
  • Abbott$3K
  • Novartis$2K
  • Boston Scientific$1K
  • Edwards Lifesciences$992
  • Heartflow, Inc.$910
  • plus $2K from 18 others

What the payments were for

  • Speaking & faculty fees$15,93455%
  • Travel & lodging$1,3465%
  • Food & beverage$11,69740%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,013 in reported general payments places this provider in the 85th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$295,543
Medicare patients
613
Services billed
2,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$157,716
Repatha SureclickEvolocumab83$79,242
XareltoRivaroxaban36$48,997
EntrestoSacubitril/Valsartan18$28,810
Praluent PenAlirocumab17$9,374
Ezetimibe164$6,381
Atorvastatin Calcium421$4,450
Rosuvastatin Calcium279$4,076
Metoprolol Succinate266$3,839
Amlodipine Besylate351$2,902
Nebivolol Hcl35$1,997
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide35$1,749
Olmesartan Medoxomil60$1,686
Losartan Potassium145$1,640
Nifedipine ErNifedipine57$1,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$157,716106 claims
Johnson & JohnsonXarelto$112$48,99736 claims
NovartisEntresto$1,610$28,81018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →